Page 49 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

Immuno-PET with 89Zr-cMab U36 in head and neck cancer
Patients received cMAb U36 IgG radiolabeled with 89Zr (74.9 ± 0.6 MBq).
The first 14 patients simultaneously received 55 MBq 186Re-labeled cMAb U36 IgG
for comparison of pharmacokinetics and biodistribution. This comparison is
beyond the scope of the present manuscript and will be reported elsewhere. The
total administered cMAb U36 dosage was 10 mg for all patients. Seventeen of 20
patients had surgery of their primary tumor, whereas all patients had unilateral (n
= 16) or bilateral (n = 4) neck dissections done 6 to 8 days after administration of 3 radiolabeled cMAb U36. All patients underwent radical neck dissection (patient 2,
14 and 16) or modified radical neck dissection comprising levels I through V,
except for patient 11, 12, and 18. Patient 11 and 18 underwent selective bilateral
neck dissection (levels II–IV + VI for patient 11, and II – IV for patient 18),
whereas patient 12 underwent selective neck dissection (II-IV) on the left side and
modified radical neck dissection (level I-VI) on the right side. The study was
reviewed and approved by the Medical Ethics Committee of the VU University
Medical Center. All patients gave written informed consent after receiving a
thorough explanation of the study.
Table 1. Patient and Tumor Characteristics
Patient Sex Age
1 F 57
2 M 57
3 F 72
4 F 53
5 M 63
6 F 58
7 M 54
8 M 55
9 F 54
10 F 65
11 M 53
12 M 59
13 F 49
14 M 58
15 M 48
16 F 63
17 M 53
18 M 58
19 M 71
20 M 60
Abbreviations: NA,
Primary tumor
Oral cavity, tongue, right
Unknown primary, base of tongue right side suspected Oropharynx, tonsil, right
Oropharynx, tonsil, right
Oropharynx, tonsil, right
Oral cavity, alveolar process and floor of mouth, left Oral cavity, tongue/floor of mouth, right
Oropharynx, tonsil, left
Hypopharynx, piriform sinus, left
Oral cavity, base of tongue, right
Larynx, glottic
Larynx, supraglottic
Residual disease after T2N0 tonsil carcinoma, left Oropharynx, base of tongue, right
Oropharynx, tonsil, right
Oropharynx, tonsil, left
Oropharynx, tonsil, right
Larynx, supraglottic, recurrence
Oropharynx, soft palate, right
Larynx, supraglottic, recurrence
not applicable
cTNM pTNM
T2N0M0 T2N1M0 TXN2aM0 TisN2bM0 T2N2bM0 T2N2bM0 T3N0M0 T3N2bM0 T4N0M0 T4N2bM0 T4N0M0 T4N2bM0 T3N0M0 T3N2bM0 T4N2aM0 T4N2bM0 T4N2bM0 T4N2bM0 T2N0M0 T2N0M0 T4N0M0 T4N0M0 T4N0M0 T4N0M0 NA NA T2N2bM0 T2N2bM0 T3N0M0 T3N1M0 T3N2bM0 T3N2b/cM0 T2N3M0 T2N3M0 NA NA T3N2cM0 T2N2cM0 NA NA
47